Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2021-07-08 Director's Dealing
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-07-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It details specific events such as amendments to the articles of incorporation, voting results from the annual meeting, and other corporate governance matters. The document includes detailed voting results for multiple proposals, including election of directors and amendments to stock plans. It is not a full annual report, audit report, or earnings release. It is not a proxy statement or solicitation but reports the results of votes and corporate actions. The document is not a brief announcement but a detailed current report on material corporate events. Therefore, the filing type corresponds to Regulatory Filings (RNS), which is the fallback category for SEC current reports (Form 8-K) that do not fit other specific categories.
2021-06-22 English
PX14A6G
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a written solicitation from a shareholder (CalPERS) urging other shareholders to support a specific shareholder proposal (#3) regarding the adoption of a majority vote standard for director elections at the upcoming Annual General Meeting. It references the Annual General Meeting date and discusses governance issues related to voting standards. The document is a proxy solicitation letter, not a report or announcement of voting results. It is intended to influence shareholder votes and provide information about the proposal. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and is a communication to shareholders requesting votes, consistent with PSI filings.
2021-06-15 English
Regulatory Filings 2021
Regulatory Filings
2021-05-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.